What is Provista Diagnostics?
Provista Diagnostics operates at the intersection of biotechnology and clinical oncology, specializing in the development of high-precision diagnostic tools. Its flagship innovation, Videssa Breast, represents a paradigm shift in breast cancer detection by utilizing advanced proteomics to analyze tumor protein biomarkers in blood samples. Unlike traditional methods that rely on circulating tumor cells or cell-free DNA, Provista's approach focuses on well-understood protein signatures, providing healthcare providers with critical clarity when interpreting complex or ambiguous mammographic findings. This technology serves as a vital adjunct to standard imaging, effectively reducing diagnostic uncertainty and improving patient outcomes in challenging clinical scenarios.
How much funding has Provista Diagnostics raised?
Provista Diagnostics has raised a total of $38.5M across 7 funding rounds:
Private Equity
$7.5M
Private Equity
$6M
Series B
$6M
Private Equity
$3.9M
Series A
$7.5M
Private Equity
$5.1M
Private Equity
$2.6M
Private Equity (2012): $7.5M, investors not publicly disclosed
Private Equity (2013): $6M, investors not publicly disclosed
Series B (2014): $6M, investors not publicly disclosed
Private Equity (2015): $3.9M featuring Groton Partners
Series A (2015): $7.5M, investors not publicly disclosed
Private Equity (2016): $5.1M with participation from MolecularMD Corp.
Private Equity (2016): $2.6M, investors not publicly disclosed
Key Investors in Provista Diagnostics
Groton Partners
Groton Partners is a merchant bank providing corporate financial advice and specialized investment opportunities, leveraging deep expertise in private equity and venture capital.
MolecularMD Corp.
MolecularMD Corporation is a diagnostics firm focused on enabling precision medicine in oncology through the development and commercialization of companion diagnostic tests.
Undisclosed Investors
What's next for Provista Diagnostics?
With the recent completion of this major strategic investment, Provista Diagnostics is poised to scale its commercial operations and expand the clinical utility of its proteomics-based diagnostic suite. The company's roadmap focuses on deepening its market penetration within the oncology sector, where the demand for non-invasive, highly accurate screening tools continues to rise. By prioritizing the integration of Videssa Breast into standard clinical workflows, Provista aims to solidify its role as a leader in precision medicine. Future growth initiatives will likely center on broadening the application of its protein biomarker platform to address additional cancer types, thereby leveraging its established technological infrastructure to capture a larger share of the diagnostic market.
See full Provista Diagnostics company page
